A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Inclusion Criteria: * Non-small cell lung adenocarcinoma * At least 2 and no more than 3 prior lines of therapy for incurable or metastatic NSCLC * Suitable for conventional single agent chemotherapy * Disease progression at study entry * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1; PS=2 patients may be considered * Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable * Adequate laboratory parameters * Willing and able to comply with the protocol and sign informed consent * Female patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participation Exclusion Criteria: * Received systemic anticancer therapy or radiation therapy within the previous 14 days * Received more than 3 lines of prior conventional therapy for advanced disease * Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy * Any condition requiring concurrent systemic immunosuppressive therapy * Known immunodeficiency disorders * Known leptomeningeal disease * Other active malignancies * Prior treatment with a cancer vaccine for this indication * Pregnant or breastfeeding